Table 2 Comparison of patient and clinical characteristics based on presence of specific ICD codes
From: Validation of diagnosis codes to identify side of colon in an electronic health record registry
Characteristic, n (%) | Colon cancer patients with specific ICD codes N = 5940 | Colon cancer patients without specific ICD codes N = 3463 |
|---|---|---|
Age at metastatic diagnosis (years), median (IQR) | 66.0 (56.0–75.0) | 66.0 (57.0–75.0) |
Age at metastatic diagnosis, years | ||
18–34 | 72 (1.2) | 46 (1.3) |
35–49 | 650 (10.9) | 353 (10.2) |
50–64 | 2014 (33.9) | 1148 (33.2) |
≥ 65 | 3204 (53.9) | 1916 (55.3) |
Sex | ||
Female | 2771 (46.6) | 1614 (46.6) |
Male | 3169 (53.4) | 1848 (53.4) |
Unknown | 0 (0) | 1 (< 0.1) |
Region | ||
Northeast | 1329 (22.4) | 826 (23.9) |
Midwest | 1214 (20.4) | 412 (11.9) |
South | 2263 (38.1) | 1074 (31.0) |
West | 826 (13.9) | 643 (18.6) |
Other/unknown | 308 (5.2) | 508 (14.7) |
Year of mCRC diagnosis | ||
2011 | 457 (7.7) | 350 (10.1) |
2012 | 795 (13.4) | 602 (17.4) |
2013 | 1218 (20.5) | 838 (24.2) |
2014 | 1359 (22.9) | 792 (22.9) |
2015 | 1547 (26.0) | 679 (19.6) |
2016 | 564 (9.5) | 202 (5.8) |
Practice type | ||
Community | 5851 (98.5) | 3072 (88.7) |
Academic | 89 (1.5) | 391 (11.3) |
Stage at diagnosis | ||
0–I | 115 (1.9) | 84 (2.4) |
II | 629 (10.6) | 364 (10.5) |
III | 1408 (23.7) | 839 (24.2) |
IV | 3639 (61.3) | 1988 (57.4) |
Unknown | 149 (2.5) | 188 (5.4) |
Tumor site | ||
Left sidea | 3061 (51.5) | NA |
Right side | 2377 (40.0) | NA |
Transverse colon | 477 (8.0) | NA |
Multiple sides | 25 (0.4) | NA |
Number of visits post diagnosis, median (Q1, Q3) | ||
Any | 31 (11, 64) | 31 (10, 70) |
Lab | 1 (0, 6) | 1 (0, 5) |
Treatment | 14 (2, 34) | 12 (1, 35) |
Office | 8 (3, 18) | 9 (3, 20) |
Other | 0 (0, 0) | 0 (0, 0) |
Non-facility | 0 (0, 0) | 0 (0, 0) |
Radiology | 1 (1, 1) | 1 (1, 1) |
Missing | 21 (0.4) | 21 (0.6) |
Line of therapy (ever in database), including maintenance | ||
1 L | 4864 (81.9) | 2729 (78.8) |
2 L | 2252 (37.9) | 1341 (38.7) |
3 L | 986 (16.6) | 642 (18.5) |
4 L | 399 (6.7) | 265 (7.7) |
1 L treatment regimens (non-maintenance) | ||
FOLFOX | 2537 (52.2)b | 1367 (50.1)b |
FOLFIRI | 903 (18.6)b | 533 (19.5)b |
FOLFOXIRI | 45 (0.9)b | 31 (1.1)b |
Bevacizumab-containing | 2736 (56.2)b | 1485 (64.4)b |
Biomarker status | ||
KRAS tested | 4004 (67.4) | 2216 (64.0) |
KRAS Positive | 925 (41.1)c | 449 (43.1)c |
NRAS tested | 1070 (18.0) | 466 (13.5) |
NRAS Positive | 36 (4.6)c | 13 (4.2)c |
BRAF tested | 1333 (22.4) | 648 (18.7) |
BRAF Positive | 101 (11.7)c | 38 (10.3)c |